Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TYBR Health
Houston, Texas, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
B3 GEL System has received FDA 510(k) clearance as a bioresorbable flowable hydrogel barrier for tissue plane protection, and is now available for post-surgical use, particularly in musculoskeletal and soft tissue repairs; no published human clinical trial data, but described as supporting improved functional recovery and reduced scarring in orthopedics by providing a temporary, resorbable barrier.[3][4][5]
- Therapeutic areas
- OtherRheumatology
- Modalities
- Hydrogel-based drug delivery therapyDevice
- Industry
- Therapeutic Medical Devices
Beyond the preview
Go deeper on TYBR Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TYBR Health.